“European Regulator Recommends Suspending Numerous Drugs Over Clinical Trial Problems”

1
121

Pharmalot’s Ed Silverman reports that a number of generic drugs, sold by Novartis and Teva Pharmaceuticals, may be pulled off of the shelves after it was revealed that they were approved based on “flawed studies.” The flawed studies all came out of an Indian clinical research organization, Semler Research Center, that was found to have “significant instances of misconduct and violations of federal regulations, including the substitution and manipulation of study subject samples.”

Article →

clinical trial problems STAT

Support MIA

MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.

$
Select Payment Method
Personal Info

Credit Card Info
This is a secure SSL encrypted payment.

Billing Details

Donation Total: $20 One Time

1 COMMENT

  1. “The findings from (the) FDA and WHO inspections call into question the quality management system in place at Semler…”

    Hahaha. FDA and WHO slamming…anyone? Stating the obvious here: Pot calling kettle black. Clearly politically motivated, otherwise it’s just a joke.

    Liz Sydney

LEAVE A REPLY